Siste måned
30 dager
0
NETTO POSISJON (NOK)
Handler
0
Kjøp
0
Salg
0
6 måneder
180 dager
+39 182 000
NETTO POSISJON (NOK)
Handler
6
Kjøp
39 182 000
Salg
0
Historikk
ℹ️ Om innsidehandel
Primærinnsidere er personer med ledelsesansvar og deres nærstående. Meldeplikt inntrer når transaksjoner når EUR 5 000 i et kalenderår.
Meldefrist: umiddelbart, senest tre virkedager. Handelsforbud 30 dager før pliktig finansiell rapportering.
Transaksjoner
Mer info 👉
| Dato | Innsider | Antall | Pris | Verdi |
|---|---|---|---|---|
| 31.08.2026 |
Trygve Lauvdal
Board Member
via Rasmussengruppen AS
|
1 170 000 | - | 5 148 000 |
| 31.08.2026 |
Trygve Lauvdal
Board Member
via Cressida AS
|
270 000 | - | 1 188 000 |
| 31.08.2026 |
Trygve Lauvdal
Board Member
via Portia AS
|
900 000 | - | 3 960 000 |
| 27.08.2026 |
Christian Åbyholm
Member of the Board
via Norda ASA
|
1 705 000 | 4.40 | 7 502 000 |
| 27.08.2026 |
Trygve Lauvdal
Member of the Board
via Rasmussengruppen AS
|
7 200 000 | 4.40 | 31 680 000 |
| 06.08.2026 |
Jakob Helding Rasmussen
Chief Technology Officer
|
1 000 000 | - | - |
| 30.01.2026 |
Susanne Stuffers
Board Member
|
150 000 | - | - |
| 30.01.2026 |
Barbara Krebs-Pohl
Chair of the Board
|
300 000 | - | - |
| 30.01.2026 |
John Beadle
Board Member
|
150 000 | - | - |
| 24.11.2025 |
Michael Engsig
Chief Executive Officer
|
46 356 | 2.16 | 100 129 |
| 10.10.2025 |
Louise Stubbe
Chief Legal Officer
|
1 200 000 | - | - |
| 10.10.2025 |
Susanne Stuffers
Chair of the Board
via Ubiquity AS
|
280 000 | 1.81 | 507 155 |
| 10.10.2025 |
Michael Engsig
Chief Executive Officer
|
55 944 | 1.79 | 100 140 |
| Vis færre ▲ | ||||
Vis alle 13 transaksjoner
▼
Pressemeldinger
| Dato | Melding |
|---|---|
| 31.08.2026 |
Mandatory notification of transaction
31 August 2026
Reference is made to the stock exchange announcements published by Nykode Therapeutics ASA (the "Company") regarding the successful pl...
|
| 27.08.2026 |
Mandatory notification of trade
28 August 2026
Reference is made to the stock exchange announcement published on 27 August 2026 by Nykode Therapeutics ASA ("Nykode" or the "Company...
|
| 06.08.2026 |
Nykode Therapeutics - Grant of share options
Oslo, Norway, August 6, 2026 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and developm...
|
| 30.01.2026 |
Nykode Therapeutics - Grant of share options
Oslo, Norway, January 30, 2026 - Reference is made to the Extraordinary General Meeting (EGM) in Nykode Therapeutics ASA held on January 21, 2026, whe...
|
| 24.11.2025 |
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Oslo, Norway, November 24, 2025 - Primary insider Michael Engsig, Chief Executive Officer of Nykode Therapeutics ASA, has today acquired 46,356 shares...
|
| 10.10.2025 |
Nykode Therapeutics – Grant of Share Options
Oslo, Norway, October 10, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and develo...
|
| 10.10.2025 |
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Ubiquity AS has today acquired 280,000 shares in Nykode Therapeutics ASA at an average price of NOK 1.8113 per share. Susanne Stuffers, Chair of the B...
|
| 10.10.2025 |
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider
Oslo, Norway, October 10, 2025 - Primary insider Michael Engsig, Chief Executive Officer of Nykode Therapeutics ASA, has today acquired 55,944 shares ...
|
| Vis færre ▲ | |
Vis alle 8 meldinger
▼